indication
as of 2026-07-01Bipolar Disorder
Competitive landscape projected to Tamoxifen’s launch window
Competitive set
12
11 approved · 1 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
66 events
2020
2024
2028
2032
2036
2040
today
Tamoxifen launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugRecruiting
US-approved 1996 · ZYPREXA Intramuscular
Phase 412 trials
Protection2041
drugCompleted
US-approved 2002 · ABILIFY
Phase 411 trials
Protection2041
drugCompleted
US-approved 1993 · RISPERDAL
Phase 47 trials
Protection2042
drugCompleted
US-approved 2006 · Erzofri extended-release
Phase 37 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
US-approved 2001 · Geodon
Phase 36 trials
Protection—
drugCompleted
US-approved 2010 · Latuda
Phase 34 trials
Protection2031
drugRecruiting
US-approved 1989 · Clozaril
Phase 42 trials
Protection2028
drugRecruiting
US-approved 2019 · CAPLYTA
Phase 31 trial
Protection2040
drugCompleted
US-approved 2009 · FANAPT
Phase 11 trial
Protection2031
Market size
prevalence as a range, not a number